

ASX / Media Announcement

Latest clinical and commercial advances in cancer
immuno-oncology
Expert briefing and Q&A

Date: Monday 13 November 2017

Time: 3:00pm – 4:00pm (Australian Eastern Daylight Time)

Location: Meeting Room 3, Level 2, Primus Hotel, 339 Pitt Street Sydney, NSW
2000

Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company developing new therapies for cancer, today announced details of its inaugural investor R&D briefing by some of the world's leading experts in immuno-oncology. Presentations and speakers include:

State of Play in Immuno-Oncology

Dr Axel Hoos, Head for Oncology R&D and Immuno-Oncology at GlaxoSmithKline (LON: GSK), Clinical Lead on Yervoy, Bristol-Myer Squibb (NYSE: BMY), Co-director of the international Cancer Immunotherapy Consortium. Non-Executive Director of Imugene

Immuno-oncology: Trends on the Horizon

Prof Christoph Zielinski, Chairman, Comprehensive Cancer Centre in Vienna, Chairman of the Centre for Eastern European Organisation for Research and Treatment of Cancer, Editor in Chief and President nominee of the European Society of Medical Oncology (ESMO). Head of Scientific Advisory Board of Imugene

The Future of Vaccines Against Cancer

Prof Ursula Wiedermann, Imugene Chief Scientific Officer, co-inventor of HER-Vaxx, co-inventor of the Mimotope platform, Professor of Vaccinology at the Medical University of Vienna.

A short Q&A will follow the presentations which will be available on the company's website and

ASX platform after the briefing. A live link to the event will be available on Facebook/imugene.

Participants are encouraged to register by Monday 30 October 2017 to ensure a seat.

For further information and to register your seat, please contact

Leslie Chong CEO

T: 0458 040 433

E: Leslie.Chong@Imugene.com

Follow us on Twitter @TeamImugene

Follow us on Facebook.com/imugene

About Imugene (ASX: IMU)

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Developed by leading scientists at the Medical University of Vienna in Austria, the peptide vaccine is constructed from several B cell epitopes of HER-2/neu. It has been shown in pre-clinical studies and in one Phase I study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

Imugene in partnership with the Medical University of Vienna is working to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.